Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03201822 · ClinicalTrials.gov registry record · NA
Intake-dependent Effect of Cocoa Flavanol Absorption, Metabolism and Excretion in Humans
A NA study, sponsored by University of California, Davis.
- Completed
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT03201822: Completed NA study, sponsored by University of California, Davis.
NCT03201822 is a NA study that has completed, run by University of California, Davis. The registered enrollment target is 14 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03201822, a NA study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
A randomized, double-masked and cross-over dietary intervention study in healthy young adult males to evaluate the concentration of F-derived metabolites in plasma and urine after single acute intakes of F-containing drinks on four different test days.
Primary Outcome
Gut microbiome derived metabolites include conjugates of 5-(3',4'-dihydroxyphenyl)-g-valerolatone metabolites
Interventions
- OTHER 100 mg of Cocoa Flavanols/70 kg BW
- OTHER 200 mg of Cocoa Flavanols/70 kg BW
- OTHER 400 mg of Cocoa Flavanols/70 kg BW
- OTHER 1000 mg of Cocoa Flavanols/70 kg BW
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2013-04-01 |
| Est. Completion | 2013-05-25 |
| Phase | NA |
What the finished NCT03201822 record still lists
NCT03201822 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 4 interventions - of which 100 mg of Cocoa Flavanols/70 kg BW is the first listed.
NCT03201822 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03201822 about?
NCT03201822 is a clinical study titled "Intake-dependent Effect of Cocoa Flavanol Absorption, Metabolism and Excretion in Humans". A randomized, double-masked and cross-over dietary intervention study in healthy young adult males to evaluate the concentration of F-derived metabolites in plasma and urine after single acute intakes of F-containing drinks on four different test days.
What is the current status of trial NCT03201822?
This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2013-04-01. Estimated completion is 2013-05-25.
What interventions are being tested in trial NCT03201822?
The interventions under investigation include: 100 mg of Cocoa Flavanols/70 kg BW (OTHER), 200 mg of Cocoa Flavanols/70 kg BW (OTHER), 400 mg of Cocoa Flavanols/70 kg BW (OTHER), 1000 mg of Cocoa Flavanols/70 kg BW (OTHER).
Who is sponsoring clinical trial NCT03201822?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03201822's enrollment target sits among peer trials
14 1909th of 2000 higher than 90 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy